Protocol Ledger

NCT04557462 · Phase III · RECRUITING

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Interventional Phase III clinical trial protocol NCT04557462 sponsored by Novartis in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-20 Enrollment: 540 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04557462
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)540 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04557462
Protocol FieldVerified Registry Value
NCT IdentifierNCT04557462
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment540 participants (ESTIMATED)
Registered Start Date2021-09-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI